TP53 gene mutations in prostate cancer progression

Anticancer Research

Volumn 30, Issue 5, 2010, Pages 1579-1586

  Ecke, Thorsten H ^a   Schlechte, Horst H ^b   Schiemenz, Katrin ^b   Sachs, Markus D ^b   Lenk, Severin V ^b   Rudolph, Birgit D ^b   Loening, Stefan A ^b  

^a HELIOS Klinikum Bad Saarow   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Mutation; p53; Progression; Prostate cancer; Tumor suppressor gene

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

CANCER GRADING; CANCER GROWTH; CANCER STAGING; CONFERENCE PAPER; GEL ELECTROPHORESIS; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; EXONS; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TEMPERATURE;

EID: 77954608766     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (47)

1. Bernards R and Weinberg RA: A progression puzzle - metastasis genes. Nature 418: 823, 2002.
2. Pisansky TM, Kahn MJ and Bostwick DG: An enhanced progostic system for clinically localized carcinoma of the prostate. Cancer 79: 2154-1261, 1997.
3. Boland R and Riccardiello L: How many mutations does it take to make a tumor? Proc Natl Acad Sci USA 96: 14675-14677, 1999.
4. Renan MJ: How many mutations are required for tumorigenesis? Implications from human cancer data. Molec Carcinog 7: 139-146, 1993.
5. Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M, Harris CC and Montesano R: IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucl Acids Res 26: 205-213, 1998.
6. Ecke TH, Schlechte HH, Hübsch A, Lenk SV, Schiemenz K, Rudolph BD and Miller K: TP53 Mutation in prostate needle biopsies - comparison with patients follow-up. Anticancer Res 27(6): 4143-4148, 2007.
7. Sidransky D and Hollstein M: Clinical implications of the p53 gene. Ann Rev Med 47: 285-301, 1996.
8. Blondal JA and Benchimol S: The role of p53 in tumor progression. Semin Cancer Biol 5: 177-186, 1994.
9. Mowat MRA: p53 in tumor progression: Life, death, and everything. Adv Cancer Res 74: 25-48, 1998. (Pubitemid 28193545)
10. Kuczyk MA, Serth J, Bokemeyer C, Machtens S, Minssen A, Bathke W, Hartmann J and Jonas U: The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer 34: 679-686, 1998. (Pubitemid 28218944)
11. Schlechte H, Lenk SV, Löning T, Schnorr D, Rudolph BD, Ditscherlein G and Loening SA: p53 tumor suppressor gene mutations in benign prostatic hyperplasia and prostate cancer. Eur Urol 34: 433-440, 1998.
12. Yu H, Levesque MA, Clark GM and Diamandis EP: Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. Br J Cancer 81: 490-495, 1999.
13. Gurova KV Roklin OW, Krivokrysenko VI, Chumakov PM, Cohen MB, Feinstein E and Gudkov AV: Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene 21: 153-157, 2002. (Pubitemid 34076388)
14. Thompson IM, Pauler DK, Goodman PJ, Tangem CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ and Coltman CA Jr: Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350: 2239-2246, 2004.
15. Partin AW and Oesterling JE: Clinical use of prostatic-specific antigen: update 1994. J Urol 152: 1358-1368, 1994.
16. Polascik TJ, Oesterling JE and Partin AW: Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 162: 293-306, 1999.
17. Moul JW: Prostate-specific antigen only progression of prostate cancer. J Urol 163: 1632-1642, 2000. (Pubitemid 30366704)
18. Critz FA: Time to achieve a prostate-specific antigen nadir of 0.2 ng/ml after simultaneous irradiation for prostate cancer. J Urol 168: 2434-2438, 2002.
19. Oberpenning F, Hamm M, Schmid HP, Hertle L and Semjonow A: Radical prostatectomy: Survival outcome and correlation to prostate-specific antigen levels. Anticancer Res 20: 4969-4972, 2000. (Pubitemid 32319061)
20. Sobin LH and Wittekind C: TNM Classification of Malignant Tumours. John Wiley & Sons, 5th edn, 1997.
21. Rosenbaum V and Riesner D: Temperature gradient gel electrophoresis. Thermodynamic analysis of nucleic acids and proteins in purified form and in cellular extracts. Biophys Chem 26: 235-246, 1987.
22. Schlechte HH, Schnorr D, Löning T, Rudolph BD, Pohrt UM and Loening SA: Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers - investigation by temperature gradient gel electrophoresis (TGGE). J Urol 157: 1049-1053, 1997.
23. Hedrum A, Pontén F, Ren Z, Lundeberg J, Pontén J and Uhlén M: Sequence-based analysis of the human p53 gene based on microdissection of tumor biopsy samples. BioTechniques 17: 118-129, 1994.
24. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ and Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinical localized prostate cancer. JAMA 280(11): 969-974, 1998. (Pubitemid 28445094)
25. Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH and deVere White RW: Complex functions of mutant p53 alleles from human prostate cancer. Prostate 51: 59-72, 2002.
26. Kubota Y, Shuin T, Uemura H, Fujinami K, Miyamoto H, Torigoe S, Dobashi Y, Kitamura H, Iwasaki Y and Dannenberg K: Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 27(1): 18-24, 1995.
27. Dahiya R, Deng G, Chen KM, Chui RM, Haugheney PC and Narayan P: P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer. Br J Cancer 74: 264-268, 1996. (Pubitemid 26254141)
28. García-Delgado M, González-Navarro CJ, Napal MC, Baldonado C, Vizmanos JL and Gullon A: Higher sensitivity of denaturing gradient gel electrophoresis than sequencing in the detection of mutations in DNA from tumor samples. Biotechniques 24: 72-76, 1998. (Pubitemid 28079288)
29. Bergh J, Norberg T, Sjögren S, Lindgren A and Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1: 1029-1034, 1995.
30. Heide I, Thiede C, Sonntag T, de Kant E, Neubauer A, Jonas S, Peter FJ, Neuhaus P, Herrmann R, Huhn D and Rochlitz CF: The status of p53 in the metastatic progression of colorectal cancer. Eur J Cancer 33: 1314-1322, 1997. (Pubitemid 27362779)
31. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H and Hotta T: Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. New Engl J Med 337(8): 529-534, 1997.
32. Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, Sherwin RN, Bozik ME and Gollin SM: The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 57: 304-309, 1997.
33. Ecke TH, Sachs MD, Lenk SV, Loening SA and Schlechte HH: TP53 gene mutations as an independent marker for urinary bladder cancer progression. Int J Mol Med 21: 655-661, 2008.
34. Nesslinger NJ, Shi XB and DeVere White RW: Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res 63: 2228-2233, 2003.
35. Kastan M-B, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
36. Forrester K Lupoid SE and Ott VL: Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 10: 2103-2111, 1995.
37. Hyytinen ER, Frierson HF Jr, Sipe TW, Li CL, Degeorges A, Sikes RA, Chung LW and Dong JT: Loss of heterozygosity and lack of mutations of the XPG/ERCC5 DNA repair gene at 13q33 in prostate cancer. Prostate 41: 190-195, 1999.
38. Hübler J, Sükösd F and Czipri M: Tibia metastasis without prostate-specific antigen (PSA) increase following radical vesiculo- prostatectomy. Int Urol Nephrol 32: 281-284, 2000. (Pubitemid 32140505)
39. Shinghal R, Yemoto C, McNeal JE and Brooks JD: Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Prostate-specific antigen. Urology 61: 380-385, 2003. (Pubitemid 36206537)
40. Balk SP, Ko YJ and Bubley GJ: Biology of prostate-specific antigen. J Clin Oncol 21: 383-391, 2003.
41. Freeland SJ, Sutter ME, Dorey F and Aronson WJ: Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 61(2): 365-369, 2003.
42. Pich A: Review: p53 expression, proliferation activity and prognosis in cancer. The Cancer J 11: 223-228, 1998.
43. Serafin AM and Bohm L: Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines. Urol Oncol 23: 123-129, 2005.
44. Quinn DI, Henshall SM, Head DR, Golovsky D, Wilson JD, Brenner PC, Turner JJ, Delprado W, Finlayson JF, Stricker PD, Grygiel JJ and Sutherland RL: Prognostic significance of nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 60(6): 1585-1594, 2000.
45. Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, Saito K, Commes T, Hayashi S, Watabe M and Watabe K: The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res 63(8): 1731-1736, 2003.
46. Chen SL, Wu YS, Shieh HY, Yen CC, Shen JJ and Lin KH: P53 is a regulator of the metastasis suppressor gene Nm23-H1. Mol Carcinog 36(4): 204-214, 2003.
47. Buchanan G, Irvine RA, Coetzee GA and Tilley WD: Contribution of the androgen receptor to prostate cancer predisposion and progression. Cancer Metastasis Rev 20(3-4): 207-223, 2001. (Pubitemid 34595269)